September 21, 2026 | Press Release
IDE approval enables initiation of the pivotal Safety in Ovarian Cancer for Average-Risk Women – Analysis (“SOARA”) Clinical Validation Study following Institutional Review Board approval WALTHAM, Mass., Sept. 21, 2026 /PRNewswire/ — Mercy...July 27, 2026 | Press Release
NEW YORK., Jul 23, 2026 /GenomeWeb/ – Based on data generated in the National Lung Screening Trial (NLST) cohort, cancer testing firm Mercy BioAnalytics believes its lung cancer early detection assay can identify cancers missed by existing low-dose computed...May 26, 2026 | Press Release
WALTHAM, Mass., May 26, 2026 /PRNewswire/ — Mercy BioAnalytics, Inc., a pioneer in blood-based early cancer detection, today announced that it will present two abstracts at the 2026 ASCO Annual Meeting highlighting results from studies using biospecimens from...February 4, 2026 | Press Release
WALTHAM, Mass., February 4, 2026 /PRNewswire/ Mercy BioAnalytics, Inc. (“Mercy”), a leader in advancing earlier and more accurate cancer detection, today announced the appointment of Darrin Crisitello as Chief Commercial Officer. Mr. Crisitello will lead the company’s...December 4, 2025 | Press Release
WALTHAM, Mass., December 04, 2025 /PRNewswire/ – Mercy BioAnalytics, a company dedicated to reducing suffering and saving lives through the early detection of cancer, today announced the appointment of Ellen Snow as its Chief Financial Officer. Snow will lead...November 20, 2025 | Press Release
WALTHAM, Mass., November 20, 2025 /PRNewswire/ — Mercy BioAnalytics, Inc., a pioneer in blood-based detection of early-stage cancer, today announced data from a groundbreaking study leveraging samples from the National Lung Screening Trial (NLST). The study...